Short answer
Intellia Therapeutics, Inc. (NTLA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $14M (up 51.3% year over year) with net income of −$101M.
Q3 2025 key financials · XBRL
- Revenue
- $14M
- +51.3% YoY · −3.3% QoQ
- Net income
- −$101M
- +25.3% YoY · −0.1% QoQ
- Operating margin
- -808.9%
- EPS (diluted)
- −$0.91
- +32.6% YoY · +7.1% QoQ
Source: XBRL data from the Intellia Therapeutics, Inc. (NTLA) Q3 2025 10-Q on SEC EDGAR. USD.
Intellia Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New clinical hold risk: FDA placed hold on MAGNITUDE and MAGNITUDE-2 Phase 3 trials for ATTR amyloidosis after Grade 4 liver events and patient death
- Most updated risk: Delays in clinical development due to evolving FDA requirements and additional preclinical data demands for CRISPR therapies
- Regulatory risk: FDA issued final 2024 guidance on Human Gene Therapy Products incorporating genome editing, affecting regulatory pathways and follow-up requirements
- Operational risk: Challenges enrolling patients in clinical trials and potential suspension due to safety concerns or regulatory noncompliance threaten near-term progress
- Financial risk: Continued net losses and no revenue from product sales, dependent on resolving clinical hold and successful commercialization to achieve profitability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Intellia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.